{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"55"}],"units":"Participants"}],"description":"Sixty patients aged 70 years and older were to be accrued to the study. The feasibility of accrual was determined that accrual of 3 patients per month in the age 70 and older range would allow for an expeditiously conducted phase II trial. If, after a 3 month start-up period, 3 or more patients aged 70 years and older were accrued per month for the duration of the trial, it was deemed reasonable to consider further trials in this elderly population.","groups":[{"description":"Patients received 1000 mg /m\\^2 of gemcitabine on Day 1 and 8 and 175 mg/m\\^2 of paclitaxel on Day 1 intravenously every 21 days for 6 cycles ( 1 cycle = 21 days)","id":"OG000","title":"Paclitaxel + Gemcitabine (Elderly Cohort: Age >= 70)"}],"paramType":"NUMBER","populationDescription":"A total of 55 patients aged 70 years and older were registered to this protocol from July, 2001 to December, 2006.","reportingStatus":"POSTED","timeFrame":"66 months (protocol activated on 7/1/2001 and closed to accrual on 12/15/2006)","title":"Determine the Feasibility of Accruing Patients With Metastatic Bladder Cancer Who Are 70 and Older to Chemotherapy Protocols","type":"PRIMARY","unitOfMeasure":"participants"}